11:29 AM
 | 
Jan 02, 2018
 |  BC Extra  |  Company News

Priority Review for Achaogen's plazomicin

FDA accepted and granted Priority Review to an NDA from Achaogen Inc. (NASDAQ:AKAO) for plazomicin (formerly ACHN-490) to treat complicated urinary tract infections (cUTIs), including pyelonephritis, and bloodstream infections due to Enterobacteriaceae in...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >